Instem plc Appointment of Chief Operating Officer
09 January 2017 - 2:30PM
RNS Non-Regulatory
TIDMINS
Instem plc
09 January 2017
9 January 2017
Instem plc
("Instem" or the "Company" or the "Group")
Appointment of Chief Operating Officer
Instem (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, announces the
appointment of Ms. MaryBeth Thompson as Chief Operating Officer of
the Group with immediate effect. Ms. Thompson, who has not been
appointed to the Instem plc main Board, will report to Phil Reason,
CEO.
Ms. Thompson has more than 18 years of experience in the life
sciences industry, with a primary focus in Regulatory Affairs and
Operations with a demonstrable track record as a leader and builder
of outsourcing services businesses.
During her tenure at PAREXEL International ("PAREXEL"), a
multinational life sciences consulting firm, and its predecessor
organisations LIQUENT and CDC Solutions, she established and
expanded the regulatory outsourcing services practice from a $1
million revenue business with 30 employees to an international
organisation across the US, Europe and India with more than $30
million of revenues and 300 employees.
Prior to PAREXEL, Ms. Thompson worked for AstraZeneca and
Wyeth-Ayerst Laboratories in pharmaceutical product development,
where she held a range of senior regulatory positions.
Phil Reason, CEO of Instem, commented: "We are delighted to have
appointed someone of MaryBeth's calibre and experience to Instem.
MaryBeth has a strong track record in building life sciences
businesses and we look forward to the benefits she will bring as we
embark upon the Company's next phase of growth."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Richard Lindley
Nick Owen
Walbrook Financial PR +44 (0) 20 7933 8000
Paul Cornelius instem@walbrookpr.com
Helen Cresswell
Sam Allen
Paul Whittington
About Instem
About Instem plc
Instem is a leading supplier of IT applications and services to
the early development healthcare market delivering compelling
solutions for data collection, analysis and regulatory submissions
management. Instem solutions are in use by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United
States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUAPGUPMGCB
(END) Dow Jones Newswires
January 09, 2017 09:30 ET (14:30 GMT)